HOUSTON--(BUSINESS WIRE)--ThromboVision, Inc., a Houston-based biomedical diagnostics company, has been awarded $1.5 million from the Texas Emerging Technology Fund to foster commercialization of the company’s groundbreaking ThromboGuide® Platelet Function Monitor (T-Guide®).
"Added to private funds we have raised, the ETF moneys will let us:
-- add the staff needed to complete development of the commercial model,
-- fund clinical trials at multiple locations,
-- develop our manufacturing processes and ramp-up manufacturing, and
-- launch the commercial T-Guide product,"
reported ThromboVision President & CEO Edward R. Teitel, MD, JD, MBA.
